PATH...low float, FDA approved drug, 59.3% investor owned. and oh yea GSK just bougth 13.9%
So look PATH over and you will find that GlaxoSmithKline GSK has purchased over 13.9% in the past 9 months and the CEO says they are in talks/looking for partnership. Could also be a buyout. Small float and a very large investor owned company. low downside risk and HUGE potential for gains on partnership.